I am seriously considering investing in this company. However, there are other needle free insulin options on the market. Such as Glygard, chlorpropamide, glibenclamide, glipizide, gliquidone, glymidine, tolazamide, tolbutamide, pioglitazone, rosiglitazone, repaglinide, Oral-Lyn, Advantajet, insulinjet, Medi-Jector Vision, Diamaxol capsules and many more. How is AOP going to compete with them?
